Top Biotech Companies (3,709)
ImmunityBio, Inc. (formerly NantKwest, Inc.) is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells. The activation of the innate immune system is key to the development of immunological memory. Over the last two decades, our founder and Executive Chairman Dr....
Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the VA Million Veteran Program (MVP). In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about...
The Cancer Research Institute (CRI) is a New York City–based nonprofit organization dedicated to advancing cancer immunotherapy. Founded in 1953, it funds scientists and researchers, supports clinical-trial networks, and promotes global collaboration and shared data to accelerate discoveries from fundamental immunology through clinical translation. Its mission is to help turn breakthrough science into life-saving treatments and create a world immune...
Enzyme design is the next grand challenge. Nature has spent billions of years evolving the enzymes we use today. Now we must design the enzymes of tomorrow. Fusing generative AI with experiment creates the opportunity to achieve this. Success will change the way we live, making better use of natural inputs and byproducts, reducing energy requirements, delivering life-changing therapies and providing...
Parachute is a new kind of plasma donation company that allows individuals to earn money while creating life-saving medicine. Plasma is used to create medicine that treats chronic illnesses, including immune disorders, liver disease, bleeding disorders, and cancer. Right now, there’s a severe plasma shortage, which is impacting patients’ access to these life-saving treatments
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a Danish biotechnology company on a mission to change lives with next generation peptide medicines. In our effort to reach our goals bonding is at the core of everything we do. Let it be discovering and developing the best new peptide drugs for patients, engaging with partners or connecting with each other....
Headquartered in Fremont, CA, Paragon Genomics is a dynamic and growing company developing and commercializing breakthrough target enrichment solutions for Next-Generation Sequencing (NGS). We are building a team of passionate scientists, engineers and business professionals who thrive in a collaborative entrepreneurial environment. Our patented CleanPlex amplicon sequencing technology solves the urgent throughput and efficiency bottlenecks of targeted sequencing workflow and...
Irvine Clinical Research is the largest independent clinical research site network on the US West Coast. Founded in 1978, the company specializes in conducting clinical trials for neurology, psychiatry, and obesity medicine. They provide clinical research opportunities and solutions to participants and sponsors, offering study-related medical care and medications at no cost to qualified participants, with a strong focus on...
AgReliant Genetics delivers one-of-a-kind, diverse genetics farmers can’t get anywhere else. Headquartered in Westfield, Indiana, AgReliant Genetics is the largest North American company focused solely on seed. AgReliant Genetics is rooted in the tradition of our two parent companies, providing direct access to a vast, one-of-a-kind genetic library for each of our brands – AgriGold, LG Seeds and PRIDE Seeds....
Attovia is creating a pipeline of biotherapeutics for the treatment of immune-mediated diseases. We leverage ATTOBODY™, our proprietary biologics platform, to generate potentially first-in-class and best-in-class multi-specifics. ATTOBODIES utilize spatial positioning technology to achieve biparatopic target engagement. The biparatopic binding mode of ATTOBODIES results in ultra-high affinity, which translates to best-in-class potency in biologic activity. ATTOBODIES offer unconstrained engineering, making them...
Innovo Research is a clinically integrated research network and population health company that partners with healthcare organizations to embed clinical research into routine patient care and value-based care workflows, aiming to improve patient outcomes and reduce costs.
Since Bio-Rad was founded 70 years ago, we have continued to provide the healthcare industry with innovative and useful products that help life science researchers accelerate the discovery process and medical diagnostic labs obtain faster, better results. Throughout our existence, we have built long-lasting customer relationships that help advance our research and development efforts in the introduction of new products...
Arbor Diagnostics, Inc. is the largest privately owned, exclusively focused, full-service women’s health diagnostics company in the U.S. It provides a broad portfolio of diagnostic and laboratory services, leveraging cutting-edge technology to improve patient outcomes. The company is dedicated to elevating women's health and creating novel solutions that allow healthcare providers to devote more time to their patients.
Sleuth is a startup that delivers done-for-you competitive intelligence insights and reports to biopharma companies and investors. We use AI agents and a proprietary database of over 100M data points and documents to power bespoke analyses for executives and a range of business-focused teams across the industry. Among our current customers are some of the largest pharma companies in the...
LeonaBio is dedicated to the development of novel therapeutics for diseases with high unmet needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS), with the goal of improving patient’s lives.
Alethios provides AI-powered tools and a software platform that revolutionizes human health research, focusing on decentralized trials, streamlined participant recruitment, and real-time data insights.
Stop wresting with cloud infrastructure and broken informatics tools. Start discovering biological insights today.
Dianthus is a biotechnology company dedicated to designing and delivering the next generation of best-in-class monoclonal antibodies with improved selectivity and potency. Led by a multidisciplinary team of seasoned biotech entrepreneurs and scientists, we are pioneering selective antibodies of validated and emerging complement targets to allow people with rare and severe autoimmune diseases live healthier lives to their fullest potential.
GlycoEra is a biotechnology company that develops bifunctional biologics and extracellular protein degraders for the treatment of autoimmune diseases. The company focuses on selectively targeting and removing circulating proteins, such as autoantibodies, to treat immune-driven disorders. Their precision immunology platform aims to provide deep and selective degradation of disease-causing proteins while avoiding the broad immunosuppressive effects typical of existing therapies.
Chemistry is the key to drug discovery, but chemical data is stuck in the twentieth century. We’re generating precise chemical datasets purpose-built to propel drug discovery into the information age — and we’re doing it on a larger scale and faster than has ever before been possible. Terray Therapeutics is a biotechnology company led by pioneers and long-time leaders in artificial...
Terray Therapeutics's Top Stability & Growth Strengths
Investor Backing & Capital Strength: The company has secured over $200 million in total funding, including an oversubscribed $120 million Series B in October 2024 led by Bedford Ridge Capital and NVentures, indicating strong investor confidence. The raise is directed to advance internal immunology programs toward clinical trials and to further enhance and scale its integrated AI platform.
Strategic Partnerships: Multi-target collaborations with Bristol Myers Squibb, Calico, Gilead, and Odyssey, along with a discovery milestone announced with BMS in December 2025, provide external validation and milestone-driven momentum. These agreements span multiple targets and disease areas, signaling durable partner demand for the platform.
Innovation-Driven Growth: Terray has advanced an experiment-integrated AI stack (tNova/EMMI, COATI, TerraBind) and reports billions of measured target–ligand interactions powering rapid design cycles. Platform updates include first-time applications like latent diffusion for small molecule design and reported gains in potency prediction speed and accuracy.






















.png)









